- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-KSB
(Mark One)
[X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the fiscal year ended SEPTEMBER 30, 1997
or
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from _________ to___________
Commission File Number 33-13110-NY
MEDTECH DIAGNOSTICS, INC.
(Name of small business issuer in its charter)
DELAWARE 11-2831380
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
201 S. BISCAYNE BLVD, SUITE 2950, MIAMI, FL 33131
(Address of principal executive offices) (Zip code)
(305) 536-8500
(Issuer's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: NONE
Securities registered pursuant to Section 12(g) of the Act: NONE
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or
for such shorter periods that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes X No__
<PAGE>
Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B contained in this form, and no disclosure will be contained, to
the best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB. [X]
State issuer's revenues for its most recent fiscal year: $8,990
As of December 2, 1997, the aggregate market value of the voting stock held by
non-affiliates of the registrant, based upon the average bid and asked prices of
such stock on that date was $1,842,750. Shares of Common Stock held by each
officer and director and by each person who owns 10% or more of the outstanding
Common Stock have been excluded in that such persons may be deemed to be
affiliates. This determination of affiliate status is not necessarily conclusive
and does not constitute an admission of affiliate status.
As of December 2, 1997, there were issued and outstanding 281,400,000 shares of
the registrant's Common Stock, par value $.00001 per share.
-2-
<PAGE>
PART I
ITEM 1 - DESCRIPTION OF BUSINESS
Medtech Diagnostics, Inc., (the "Company"), was incorporated under the laws of
the State of Delaware on October, 27, 1986. In October 1991, the Company
suspended all operations, except for necessary administrative matters and ceased
to be an operating company.
In January 1993, the Company consummated an agreement with Beverley Hills
Bancorp. ("BHB") wherein BHB acquired a controlling interest in the Company. On
June 5, 1996, BHB sold its entire interest in the Company's Common Stock to
Messrs. Steven N. Bronson and James S. Cassel, who constitute the present
management of the Company.
The Company is currently seeking merger or acquisition partners so as to best
utilize the Company's cash and corporate structure.
The Company currently has no full time employees, its Chairman, President and
Chief Executive Officer is Steven N. Bronson and James S. Cassel serves as the
Company's Secretary and Treasurer.
ITEM 2 - DESCRIPTION OF PROPERTY
The Company presently maintains its corporate and administrative offices at 201
S. Biscayne Blvd., Suite 2950, Miami, Florida 33131. The Company utilizes a
portion of the premises occupied by Barber & Bronson Incorporated, a full
service brokerage investment banking firm, with which both Messrs. Bronson and
Cassel are principals. Due to the curtailed nature of the Company's operations
Barber & Bronson Incorporated has, until further notice, waived the payment of
rent by the Company. No rent was paid in the fiscal years ended September 30,
1997 and 1996.
ITEM 3 - LEGAL PROCEEDINGS
As of December 2, 1997, the Company is not a party to any material legal
proceedings.
ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted to a vote of security holders by the Company during
the fourth quarter of the fiscal year covered by this report.
-3-
<PAGE>
PART II
ITEM 5 - MARKET FOR COMMON STOCK AND RELATED STOCKHOLDER MATTERS
The Company's Common Stock, par value $.00001 per share, is traded in the
over-the counter market.
The following table sets forth the range of high and low closing bid prices for
the Company's Common Stock for the periods indicated as reported by the National
Quotation Bureau, Inc. These prices represent quotations between dealers, do not
include retail markups, mark down or commissions, and do not necessarily
represent actual transactions.
<TABLE>
<CAPTION>
BID PRICE
---------------------------------
CALENDAR YEARS LOW HIGH
- -------------- ------- -------
<S> <C> <C> <C>
1997: First Quarter $.00125 $.00125
Second Quarter $.00125 $.00125
Third Quarter $.00125 $.00125
Fourth Quarter (through
December 2) $.00125 $.00125
1996: First Quarter $.00125 $.00125
Second Quarter $.00125 $.00125
Third Quarter $.00125 $.00125
Fourth Quarter $.00125 $.00125
</TABLE>
As of December 2, 1997, the National Quotation Bureau, Inc. reported that the
closing bid and asked prices on the Company's Common Stock were $.00125 and
$.025, respectively.
As of December 2, 1997, the Company's Common Stock was held by approximately 90
record holders, who the Company believes held for in excess of 300 beneficial
holders.
The Company has never paid any cash dividends on its Common Stock and does not
anticipate paying any cash dividends in the foreseeable future.
ITEM 6 - MANAGEMENT'S DISCUSSION AND ANALYSIS
GENERAL
In October 1991, the Company suspended all operations except for necessary
administrative matters and ceased to be an operating company. As such, for the
fiscal year ended September 30, 1997, the Company had no revenues from
operations. Given the virtual suspension of the Company's operations except for
necessary administrative matters, the Company's officers have waived further
compensation.
RESULTS OF OPERATIONS
During the year ended September 30, 1997 ("Fiscal 97"), the Company earned
interest of $8,990, as compared to $6,589 interest earned in the year ended
September 30, 1996 ("Fiscal 96"), an increase of
-4-
<PAGE>
$2,401. During Fiscal 97, the Company incurred general & administrative expenses
of $20,464, an increase of $2,465 over Fiscal 96 expenses of $17,999. This
increase was primarily due to additional printing costs associated with the
Company's Securities and Exchange Commission filings via EDGAR.
LIQUIDITY AND CAPITAL RESOURCES
During Fiscal 97, the Company satisfied its working capital needs from cash on
hand at the beginning of the year and cash generated from interest income during
the year. As of September 30, 1997, the Company had working capital of $225,132.
This working capital is expected to be sufficient to provide the Company with
sufficient capital while it seeks a merger, acquisition or other arrangement by
and between the Company and a viable operating entity, although there is no
assurance that this will occur.
ITEM 7 - FINANCIAL STATEMENTS
The financial statements and related notes are included as part of this report
as indexed in the appendix on page 10.
ITEM 8 - CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
Not applicable.
-5-
<PAGE>
PART III
ITEM 9 - DIRECTORS AND EXECUTIVE OFFICERS
The executive officers and directors of the Company are as follows:
<TABLE>
<CAPTION>
NAME AGE POSITION
- ---- --- --------
<S> <C> <C>
Steven N. Bronson 32 Chairman, President and Chief Executive Officer
James S. Cassel 43 Secretary, Treasurer and Director
</TABLE>
Steven N. Bronson has served as the Company's Chairman, President and Chief
Executive Officer since June 1996. Due to the curtailed nature of the Company's
business activities, Mr. Bronson does not devote full time to the affairs of the
Company. Mr. Bronson is the President of Barber & Bronson Incorporated, a full
service securities brokerage and investment banking firm and has held that
position since 1991. Mr. Bronson also sits on the Board of Directors of the
Regional Investment Bankers Association, an industry association engaged in
capital formation and the distribution of securities.
James S. Cassel has served as the Company's Secretary, Treasurer and as a
director since June 1996. Due to the curtailed nature of the Company's business
activities, Mr. Cassel does not devote full time to the affairs of the Company.
Mr. Cassel is the Executive Vice President of Barber & Bronson Incorporated, a
full service securities brokerage and investment banking firm and has held that
position since 1996. Prior to joining Barber & Bronson Incorporated, Mr. Cassel
was the managing partner of the Miami office of Broad and Cassel, a Florida
based law firm. He was a member of the American Association of Arbitrators and
NASD Board of Arbitrators. Mr. Cassel received his bachelor's degree from
American University in 1976 and his J.D. from the University of Miami School of
Law in 1979.
The Company's By-Laws provide for the election of directors at the annual
meeting of shareholders, such director to hold office until the next annual
meeting and until their successors are duly elected and qualified. The By-Laws
also provide that the annual meeting of shareholders be held each year at such
time, data and place as the Board of Directors shall determine by resolution.
Directors may be removed at any time for cause by the Board of Directors and
with or without cause be a majority of the votes cast by the shareholders
entitled to vote for the election of directors.
Officers will normally be elected at the annual meeting of the Board of
Directors held immediately following the annual meeting of shareholders, to hold
office for the term for which elected and until their successors are Directors
at any time with or without cause.
ITEM 10 - EXECUTIVE COMPENSATION
Due to the reduced level of the Company's operations, no compensation has been
paid to any of the Company's executive officers during the fiscal year ended
September 30, 1997.
The Company does not presently have any option, bonus, retirement or profit
sharing plans.
-6-
<PAGE>
ITEM 11 - SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information regarding beneficial
ownership of Common Stock as of October 31, 1997 by (i) each person or entity
known by the Company to own beneficial more than 5% of the outstanding Common
Stock, (ii) each director, (iii) each executive officer, and (iv) all directors
and executive officers of the Company as a whole. Except as otherwise noted
below, the listed beneficial owner has sole voting and investment power with
respect to such shares and the address of the listed beneficial owner is that of
the Company.
NUMBER OF PERCENT
NAME AND ADDRESS SHARES OWNED OF CLASS
- ---------------- ------------ --------
Steven N. Bronson 70,500,000 25.05%
James S. Cassel
and Mindy E. Cassel 70,500,000 25.05%
Estate of Jeffrey Wenig (1)
9 Dickens Avenue
Dix Hills, NY 20,000,000 7.10%
All directors and executive officers
as a group (2 persons) 141,000,000 50.10%
ITEM 12 - CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The Company utilizes a portion of the premises occupied by Barber & Bronson
Incorporated, with which both Messrs. Bronson and Cassel are principals. Due to
the curtailed nature of the Company's operations Barber & Bronson Incorporated
has, until further notice, waived the payment of rent by the Company. No rent
was paid in the fiscal years ended September 30, 1997 and 1996.
ITEM 13 - EXHIBITS AND REPORTS ON FORM 8-K
(A) EXHIBITS
The following exhibits are filed as part of this Annual Report on Form
10-KSB for the year ended September 30, 1997.
EXHIBIT NO. EXHIBIT DESCRIPTION
----------- -------------------
3.1 Articles of Incorporation of the Company. (1)
3.2 By-Laws of the Company. (1)
-7-
<PAGE>
27 Financial Data Schedule (EDGAR version only).
- ---------------
(1) Incorporated herein by reference to the same numbered Exhibit
to the Company's earlier Form 10-KSB filings under Commission
file number 33-13110-NY.
(B) REPORTS ON FORM 8-K
No reports on Form 8-K were filed by the Company during the fourth
quarter of the year ended September 30, 1997.
(C) FINANCIAL STATEMENTS
The financial statements and related notes of the Company begin on page
12 in the appendix. The report of the independent certified public
accountants on the Company's financial statements begin on page 11 in
the appendix.
(D) FINANCIAL STATEMENT SCHEDULES
Financial statement schedules have been omitted because of the absence
of conditions under which they are required or because the required
material information is included in the financial statements or related
notes included herein.
-8-
<PAGE>
SIGNATURES
In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934,
the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
MEDTECH DIAGNOSTICS, INC.
December 9, 1997 by: /S/ STEVEN N. BRONSON
---------------------
Steven N. Bronson
President and Chief Executive Officer
In accordance with the Securities Exchange Act of 1934, this report has been
signed below by the following persons on behalf of the registrant and in the
capacities and on the dates indicated.
December 9, 1997 by: /S/ STEVEN N. BRONSON
---------------------
Steven N. Bronson
President and Chief Executive Officer
December 9, 1997 by: /S/ JAMES S. CASSEL
-------------------
James S. Cassel
Secretary, Treasurer and Principal
Accounting Officer
-9-
<PAGE>
APPENDIX
ITEM 7 - FINANCIAL STATEMENTS
<TABLE>
<CAPTION>
MEDTECH DIAGNOSTICS, INC.
INDEX TO FINANCIAL STATEMENTS
Page:
<S> <C>
Report of Independent Public Accountants 11
Balance Sheet 12
Statements of Operations 13
Statements of Stockholders' Equity 14
Statements of Cash Flows 15
Notes to Financial Statements 16
</TABLE>
-10-
<PAGE>
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
Board of Directors and Stockholders
Medtech Diagnostics, Inc.
We have audited the accompanying balance sheet of Medtech Diagnostics, Inc. as
of September 30, 1997 and the related statements of operations, changes in
stockholders' equity and cash flows for the years ended September 30, 1997 and
1996. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Medtech Diagnostics, Inc. as of
September 30, 1997 and the results of its operations and its cash flows for the
years ended September 30, 1997 and 1996, in conformity with generally accepted
accounting principles.
The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. The Company previously had been in the
development stage and during fiscal 1992 suspended all operations except for
necessary administrative matters. The Company has not recorded any revenue from
operations and has incurred losses since inception, which raises substantial
doubt about its ability to continue as a going concern. Management's plans in
regard to these matters are described in Note 1. These financial statements do
not include any adjustments that may result from the outcome of this
uncertainty.
GRANT THORNTON LLP
Melville, New York
November 25, 1997
-11-
<PAGE>
MEDTECH DIAGNOSTICS, INC.
Balance Sheet
September 30, 1997
ASSETS
CURRENT ASSETS
Cash and cash equivalents $ 231,882
============
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable and accrued expenses $ 6,750
------------
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Common stock, par value $.00001; authorized,
500,000,000 shares; 281,400,000 issued and outstanding 2,814
Capital in excess of par value 1,436,745
Accumulated deficit (1,214,427)
------------
225,132
------------
$ 231,882
============
The accompanying notes are an integral part of this statement
-12-
<PAGE>
MEDTECH DIAGNOSTICS, INC.
Statements of Operations
For the years ended September 30,
1997 1996
---- ----
INTEREST INCOME $ 8,990 $ 6,589
COSTS AND EXPENSES
General & administrative 20,464 17,999
--------- ---------
NET LOSS $ 11,474 $ 11,410
========= =========
NET LOSS PER COMMON SHARE $ - $ -
========= =========
WEIGHTED AVERAGE NUMBER OF
SHARES OUTSTANDING 281,400,000 281,400,000
=========== ===========
The accompanying notes are an integral part of these statements
-13-
<PAGE>
<TABLE>
<CAPTION>
MEDTECH DIAGNOSTICS, INC.
Statements of Changes in Stockholders' Equity
For the years ended September 30, 1997 and 1996
COMMON STOCK CAPITAL IN
----------------------------- EXCESS OF ACCUMULATED
SHARES AMOUNT PAR VALUE DEFICIT TOTAL
----------- ------- ---------- ------------- --------
<S> <C> <C> <C> <C> <C>
BALANCE, OCTOBER 1, 1995 281,400,000 $ 2,814 $1,436,745 $(1,191,543) $248,016
Net loss - - - (11,410) (11,410)
----------- ------ --------- ---------- -------
BALANCE, SEPTEMBER 30, 1996 281,400,000 2,814 1,436,745 (1,202,953) 236,606
Net loss - - - (11,474) (11,474)
----------- ------ --------- ---------- -------
BALANCE, SEPTEMBER 30, 1997 281,400,000 $ 2,814 $1,436,745 $(1,214,427) $225,132
=========== ====== ========= ========== =======
</TABLE>
The accompanying notes are an integral part of these statements
-14-
<PAGE>
<TABLE>
<CAPTION>
MEDTECH DIAGNOSTICS, INC.
Statements of Cash Flows
For the years ended September 30,
1997 1996
---- ----
<S> <C> <C>
OPERATING ACTIVITIES
Net loss $ (11,474) $ (11,410)
Adjustments to reconcile net loss to
net cash used in operating activities:
Changes in operating assets and liabilities:
Decrease in accounts payable
and accrued expenses (250) (3,950)
--------- --------
Net cash used in operating activities (11,724) (15,360)
--------- --------
NET DECREASE IN CASH AND CASH EQUIVALENTS (11,724) (15,360)
CASH AND CASH EQUIVALENTS BEGINNING OF YEAR 243,606 258,966
-------- --------
CASH AND CASH EQUIVALENTS END OF YEAR $ 231,882 $ 243,606
======== ========
Supplemental disclosure:
Income taxes paid $ 521 $ 600
======== =========
</TABLE>
The accompanying notes are an integral part of these statements
-15-
<PAGE>
MEDTECH DIAGNOSTICS, INC.
Notes to Financial Statements
September 30, 1997 and 1996
NOTE 1 - ORGANIZATION AND BASIS OF PRESENTATION
ORGANIZATION AND OPERATIONS: Medtech Diagnostics Inc., previously a development
stage company incorporated under the laws of Delaware on October 27, 1986, was
engaged in research and testing which it hoped would lead to the development of
a home Pap Test Kit. In 1991, the Company suspended all operations except for
necessary administrative expenses. The Company is currently seeking companies to
merge with or acquire, so as to best utilize the Company's cash and corporate
structure.
BASIS OF PRESENTATION: The accompanying financial statements have been prepared
assuming that the Company will continue as a going concern. The Company has
sustained losses since inception resulting in an accumulated deficit of
$1,214,427 as of September 30, 1997. This raises substantial doubt about the
Company's ability to continue as a going concern. These financial statements do
not include any adjustments that may result should the Company be unable to
continue in existence.
The Company is currently seeking companies to merger with or acquire, so as to
best utilize the Company's cash and corporate structure.
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES
NET LOSS PER SHARE: Net loss per share is computed by dividing net loss by the
weighted average number of common shares outstanding during the period.
CASH AND CASH EQUIVALENTS: All short-term investments with a maturity of three
months or less when purchased are considered to be cash equivalents. Cash
equivalents, which consist primarily of certificates of deposit are stated at
cost which approximates fair value.
USE OF ESTIMATES: The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts and contingency disclosures
included in the financial statements. Ultimate results could differ from these
estimates.
CONCENTRATION OF CREDIT RISK: Financial instruments which potentially subject
the Company to concentrations of credit risk consist principally of cash and
cash equivalents. The Company places its cash and cash equivalents with
institutions insured by the Federal Deposit Insurance Corporation up to
$100,000. As of September 30, 1997, uninsured balances aggregated approximately
$131,000.
RECENTLY ISSUED ACCOUNTING STANDARDS: In February 1997, the Financial Accounting
Standards Board released Statement of Financial Accounting Standards No. 128,
Earnings per Share ("SFAS No. 128"), which changes the computation and
disclosure of earnings per share. SFAS No. 128 is effective for both interim and
annual period ending after December 15, 1997, and earlier application is not
permitted. Under the Company's current capital structure, the adoption of SFAS
No. 128 will not have a material impact on the Company's determination of
earnings per share.
-16-
<PAGE>
MEDTECH DIAGNOSTICS, INC.
Notes to Financial Statements (continued)
September 30, 1997 and 1996
NOTE 3 - INCOME TAXES
Statement of Financial Accounting Standards No. 109, Accounting for Income Taxes
("SFAS No. 109") requires the use of an asset and liability approach in
accounting for income taxes. Deferred income taxes reflect the net tax effects
of temporary differences between the carrying amounts of assets and liabilities
for financial reporting purposes and the amounts used for income tax purposes. A
valuation allowance is established to reduce deferred tax assets if it is more
likely than not that all, or some portion, of such deferred tax assets will not
be realized. The ultimate realization of the deferred tax asset depends on the
Company's ability to generate sufficient taxable income in the future.
As of September 30, 1997, the Company had net operating loss carryforwards of
approximately $1,214,000 for income tax purposes, which expire in varying
amounts beginning September 30, 2002 through 2012. Federal tax rules impose
limitations on the use of net operating losses following certain changes in
ownership. Such a change of control occurred during the fiscal year ended
September 30, 1996. As a result, the Company's ability to utilize the net
operating loss carryforwards existing prior to the ownership change is subject
to an annual limitation of approximately $14,000 and accordingly, the maximum
net operating loss presently available is approximately $230,000.
The Company has determined that the realization of the loss carryforwards does
not meet the recognition criteria under SFAS No. 109 and, accordingly, a 100%
valuation allowance has been established for the tax benefit of these items.
NOTE 4 - RELATED PARTY TRANSACTIONS
Currently, the Company, at no charge to the Company, utilizes a portion of the
premises occupied by a company of which the Company's officers are principals.
Further that company provides certain administrative services to the Company at
no charge to the Company.
Through June 5, 1996, the Company, at no charge to the Company, occupied office
premises from a company principally owned by the Company's former president, who
is the wife of a former director.
NOTE 5 - CHANGE IN OWNERSHIP AND CONTROL
On June 5, 1996 pursuant to the terms of a Stock Purchase Agreement (the
"Agreement"), Beverly Hills Bancorp sold 141,000,000 shares of the Company's
Common Stock, representing 50.10% of the Company's issued and outstanding Common
Stock to Steven N. Bronson and James S. Cassel (the "Purchasers"). The Agreement
provided for a purchase price of $165,000, which consideration was paid with the
Purchasers' own funds. Upon consummation of the transaction, in accordance with
its terms, the Company's chairman and a director resigned from the Company's
Board of Directors. By resolution of the remaining directors dated June 5, 1996,
Messrs. Bronson and Cassel were appointed the Company's Board of Directors and
subsequently, the remaining directors resigned.
-17-
<PAGE>
EXHIBIT INDEX
EXHIBIT DESCRIPTION
- ------- -----------
27 Financial Data Schedule
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> SEP-30-1997
<PERIOD-START> OCT-1-1996
<PERIOD-END> SEP-30-1997
<CASH> 231,882
<SECURITIES> 0
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 231,882
<PP&E> 0
<DEPRECIATION> 0
<TOTAL-ASSETS> 231,882
<CURRENT-LIABILITIES> 6,750
<BONDS> 0
0
0
<COMMON> 2,814
<OTHER-SE> 222,318
<TOTAL-LIABILITY-AND-EQUITY> 231,882
<SALES> 0
<TOTAL-REVENUES> 0
<CGS> 0
<TOTAL-COSTS> 20,464
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> (8,990)
<INCOME-PRETAX> (11,474)
<INCOME-TAX> 0
<INCOME-CONTINUING> (11,474)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (11,474)
<EPS-PRIMARY> 0
<EPS-DILUTED> 0
</TABLE>
